Artivion, Inc. (AORT) AI Stock Analysis

Artivion, Inc., formerly known as CryoLife, Inc., manufactures, processes, and distributes medical devices and implantable human tissues. Headquartered in Kennesaw, Georgia, the company provides surgical solutions including BioGlue, PhotoFix pericardial patches, and cardiac preservation services such as CryoVein and CryoArtery. Its aortic and cardiovascular intervention products include E-vita Open Plus, E-vita Open Neo, E-xtra, E-nside, E-vita THORACIC 3G, and E-nya. Artivion also produces E-ventus BX, E-liac, E-tegra, synthetic vascular grafts, PerClot hemostats, cardiac laser therapy products, On-X prosthdetic heart valves, CarbonAid catheters, Chord-X sutures, and medical dissection stents.

Artivion increased revenue from $298.8M in FY2021 to $441.3M in FY2025, recording a 5-year revenue CAGR of 11.8% from FY2020 to FY2025. Annual revenue grew 13.6% in FY2025, following 9.8% in FY2024 and 12.8% in FY2023. Gross margin declined from 66.1% in FY2021 to 61.3% in FY2025, while operating margin rose from 2.7% in FY2021 to 10.0% in FY2024 before settling at 6.1% in FY2025. Following annual net losses from FY2021 through FY2024, the company generated net income of $9.8M and EPS of $0.63 in FY2025. For the latest quarter ended June 30, 2026, revenue increased 11.3% year-over-year, bringing trailing twelve-month revenue to $471.5M with an operating margin of 9.0%.

As of June 30, 2026, Artivion held $77.3M in cash and short-term investments against total debt of $408.0M, resulting in net debt of $330.7M and a debt-to-equity ratio of 0.92. Total assets were $1.07B compared to shareholders' equity of $445.6M, alongside a current ratio of 3.47. Operating cash flow rose to $38.1M in FY2025, but capital expenditures of $39.0M led to free cash flow of -$911,000. Over 5 years, the company's share count expanded 24.0%.

Artivion has a market cap of $1.06B and an enterprise value of $1.48B. The stock trades at a forward P/E of 35.3x, higher than the 17.3x forward P/E median of its US-listed Healthcare peers. Its EV to EBITDA multiple is 28.9x compared to the peer median of 12.0x, though its price-to-sales multiple of 2.3x is below the peer median of 4.1x. Over the past year, the stock fell 47.6%, lagging the 16.8% return of the S&P 500 (SPY). Over 5 years, the stock gained 2.0%, trailing the S&P 500 return of 83.0%.

Artivion is covered by analysts who assign 6 Strong Buy and 2 Buy ratings, with zero Hold, Sell, or Strong Sell recommendations. The mean price target is $42.15, which is 93.5% above the last closing price of $21.78. For the current fiscal year ending December 31, 2026, consensus estimates project revenue of $490.4M and EPS of $0.40. For the next fiscal year, 6 analysts forecast revenue of $543.2M and EPS of $0.75, representing 88.0% EPS growth. Artivion beat EPS estimates in 1 of the last 4 quarters, and its next earnings date is November 5, 2026.

This page is an AI-written research summary of Artivion, Inc. (AORT). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: AORT income statement, AORT balance sheet, AORT key metrics, AORT analyst forecast, AORT chart. See the AORT stock overview for the latest quote and news.